The
following financial instruments were not included in the diluted loss per share calculations as of the three months ended March 31, 2026,
and 2025 because their effect was anti-dilutive:
Schedule of Anti-dilutive Loss Per Share
| | |
March
31, 2026 | | |
March
31, 2025 | |
| Warrants to purchase common stock | |
| 351,528 | | |
| 351,537 | |
| | |
| | | |
| | |
| Options | |
| 1,870,615 | | |
| 1,747,789 | |
| | |
| | | |
| | |
| Restricted stock awards units | |
| 426,784 | | |
| 424,656 | |
| | |
| | | |
| | |
| Total | |
| 2,648,927 | | |
| 2,523,982 | |
|